149 related articles for article (PubMed ID: 7523272)
1. Expression of mucin core protein of mammary type in primary liver cancer.
Sasaki M; Nakanuma Y
Hepatology; 1994 Nov; 20(5):1192-7. PubMed ID: 7523272
[TBL] [Abstract][Full Text] [Related]
2. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
3. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
Batmunkh E; Tátrai P; Szabó E; Lódi C; Holczbauer A; Páska C; Kupcsulik P; Kiss A; Schaff Z; Kovalszky I
Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
6. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
Sasaki M; Nakanuma Y; Ho SB; Kim YS
Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
[TBL] [Abstract][Full Text] [Related]
8. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
Tanaka S; Hirohashi K; Uenishi T; Yamamoto T; Hamba H; Kubo S; Tanaka H; Shuto T; Ogawa M; Kinoshita H
Hepatogastroenterology; 2004; 51(57):839-41. PubMed ID: 15143930
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
10. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma.
Zhang K; Tang W; Qu X; Guo Q; Inagaki Y; Seyama Y; Abe H; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Hepatogastroenterology; 2009; 56(93):960-3. PubMed ID: 19760920
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma.
Ichikawa T; Yamamoto T; Uenishi T; Tanaka H; Takemura S; Ogawa M; Tanaka S; Suehiro S; Hirohashi K; Kubo S
J Hepatobiliary Pancreat Surg; 2006; 13(3):245-51. PubMed ID: 16708303
[TBL] [Abstract][Full Text] [Related]
12. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
Histopathology; 2006 Jul; 49(1):35-44. PubMed ID: 16842244
[TBL] [Abstract][Full Text] [Related]
13. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
[TBL] [Abstract][Full Text] [Related]
15. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
Zhang F; Chen XP; Zhang W; Dong HH; Xiang S; Zhang WG; Zhang BX
Histopathology; 2008 Jan; 52(2):224-32. PubMed ID: 18184271
[TBL] [Abstract][Full Text] [Related]
16. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
[TBL] [Abstract][Full Text] [Related]
17. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma.
Varnholt H; Asayama Y; Aishima S; Taguchi K; Sugimachi K; Tsuneyoshi M
Oncol Rep; 2002; 9(1):35-41. PubMed ID: 11748452
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
19. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
[TBL] [Abstract][Full Text] [Related]
20. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
